Anna Foster is an embalmer with 11 years of experience in Carrollton, MO. She speaks out for the first time in this exclusive interview. The big news is that she found the unusual clots in 93% of the

(NaturalHealth365) Worldwide data sheds light on worrying possibility of COVID jab-induced immune system destruction.

Get the latest statistics on COVID-19 vaccines adverse events reported to VAERS website here.

In this video, I review a one of the most recent large systemic metanalysis that shows how optimizing vitamin D levels may be the best defense for reducing COVID-19 infection rates and risk of hospitalization and death. The study, published in Nutrients in Oct 2021 can be found here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541492/ For more info on Vitamin D, read this article: https://drjockers.com/vitamin-d-respiratory-infections/

Sleezballs is too mild a term for the scum of the Earth who have taken over the field of medicine and public health. Just for starters, Fauci and Gates are running neck and neck for the most disgusting examples of what humans can become, and the CEO of Pfizer seems to take the cake for... View Article

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the greatest worldwide pandemic since the 1918 flu. The consequences of the coronavirus disease 2019 (COVID-19) are devastating and represent the current major public health issue ...

Muscle fatigue and cognitive disturbances persist in patients after recovery from acute COVID-19 disease. However, there are no specific treatments for post-COVID fatigue. Objective: To evaluate the efficacy and safety of the health supplements ImmunoSEB ...

(NaturalHealth365) New York governor admits more than forty percent of hospitalizations in the state are for reasons other than COVID.

(NaturalHealth365) In this interview, Israeli immunologist admits to multiple serious mistakes made during COVID-19 pandemic.

(NaturalHealth365) In an editorial published in BMJ, Peter Doshi and colleagues demand immediate release of COIVD shot data.

(NaturalHealth365) A recent study from Wuhan, China, reveals COVID shot triggers physiological changes in humans, weakens the immune system.

A cardiac MRI of college athletes who had COVID-19 is seven times more effective in detecting inflammation of ...

(NaturalHealth365) Analysis of data from 145 countries shows causal relationship between COVID jab rollout and increase in deaths and cases.

(NaturalHealth365) Canadian data show most hospitalized patients with COVID are fully vaxxed. Does the jab do more harm than good?

It is not normal for young athletes to suffer cardiac arrest or death while playing sport, but most of these come shortly after a COVID shot.

Cell Discovery - Comprehensive investigations revealed consistent pathophysiological alterations after...

This article may be...

(NaturalHealth365) After two long years, only now CDC admits majority of COVID deaths had multiple comorbid conditions.

Use your smartphone to report any side effects after getting the COVID-19 vaccine, as well as reminders if you need a second dose.

It's is an antioxidant, an anti-viral, and an anti-inflammatory with no reported adverse events in published clinical trials. So why not give it to COVID patients?

(NaturalHealth365) After two years of testing mania the CDC admits that the PCR tests used to drive pandemic fears are not reliable.

(NaturalHealth365) In an open letter, top immunologist calls out the government for its deplorable handling of the COVID-19 pandemic.

COVID sentiment is changing among top ranks in the U.S. and Europe through the Chinese are continuing to close up cities, shut down vital ports (threatening the world’s supply chain with a huge shock), and believe it or not, are putting their citizens in little boxes. However, talking about a sea of COVID change, the... View Article

In this brief communication we are showing original research results with early estimates from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-2 Omicron variant (B.1.1.529) up to five months after a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines. Our study provides evidence of protection against infection with the Omicron variant after completion of a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines; in particular, we found a VE against the Omicron variant of 55.2% (95% confidence interval (CI): 23.5 to 73.7%) and 36.7% (95% CI: 69.9 to 76.4%) for the BNT162b2 and mRNA-1273 vaccines, respectively, in the first month after primary vaccination. However, the VE is significantly lower than that against Delta infection and declines rapidly over just a few months. The VE is re-established upon revaccination with the BNT162b2 vaccine (54.6%, 95% CI: 30.4 to 70.4%). ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study did not receive any funding ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: We used only administrative register data for the study. According to Danish law, ethics approval is exempt for such research, and the Danish Data Protection Agency, which is a dedicated ethics and legal oversight body, thus waives ethical approval for our study of administrative register data, when no individual contact of participants is necessary and only aggregate results are included as findings. The study is therefore fully compliant with all legal and ethical requirements and there are no further processes available regarding such studies. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes De-identified data are available for access to members of the scientific and medical community for non-commercial use only upon reasonable request to the authors

Background The incidence of SARS-CoV-2 infection, including among those who have received 2 doses of COVID-19 vaccines, has increased substantially since Omicron was first identified in the province of Ontario, Canada. Methods Applying the test-negative design to linked provincial data, we estimated vaccine effectiveness against infection (irrespective of symptoms or severity) caused by Omicron or Delta between November 22 and December 19, 2021. We included individuals who had received at least 2 COVID-19 vaccine doses (with at least 1 mRNA vaccine dose for the primary series) and used multivariable logistic regression to estimate the effectiveness of two or three doses by time since the latest dose. Results We included 3,442 Omicron-positive cases, 9,201 Delta-positive cases, and 471,545 test-negative controls. After 2 doses of COVID-19 vaccine, vaccine effectiveness against Delta infection declined steadily over time but recovered to 93% (95%CI, 92-94%) ≥7 days after receiving an mRNA vaccine for the third dose. In contrast, receipt of 2 doses of COVID-19 vaccines was not protective against Omicron. Vaccine effectiveness against Omicron was 37% (95%CI, 19-50%) ≥7 days after receiving an mRNA vaccine for the third dose. Conclusions Two doses of COVID-19 vaccines are unlikely to protect against infection by Omicron. A third dose provides some protection in the immediate term, but substantially less than against Delta. Our results may be confounded by behaviours that we were unable to account for in our analyses. Further research is needed to examine protection against severe outcomes. ### Competing Interest Statement K.W. is CEO of CANImmunize and serves on the data safety board for the Medicago COVID-19 vaccine trial. The other authors declare no conflicts of interest. ### Funding Statement This work was supported by the Canadian Immunization Research Network (CIRN) through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CNF 151944). This project was also supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference Group and the COVID-19 Immunity Task Force. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH). J.C.K. is supported by Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine. P.C.A. is supported by a Mid-Career Investigator Award from the Heart and Stroke Foundation. This work was supported by Public Health Ontario. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). This study was supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontarios ongoing response to COVID-19 and its related impacts. The study sponsors did not participate in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI) and by Cancer Care Ontario (CCO). However, the analyses, conclusions, opinions and statements expressed herein are solely those of the authors, and do not reflect those of the funding or data sources; no endorsement by ICES, MOH, MLTC, OHDP, its partners, the Province of Ontario, CIHI or CCO is intended or should be inferred. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. The use of the data in this project is authorized under section 45 and approved by ICES Privacy and Legal Office. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca).

While nutrient deficiencies increase loss of smell and taste, there are other reasons as well. Infections increase the utilization of zinc and vitamin A heavily which contributes to loss of smell and taste. However, if you've tried using quality zinc and vitamin A supplements to no avail, perhaps your sense of smell and taste is associated with higher levels of oxidative stress and deficiencies in various antioxidants. Infections increase the responsiveness by your immune system. An enhanced immune system increases oxidative stress. Why? To kill the pathogen. Oxidative stress kills bacteria, viruses and other pathogens. Issue is oxidative stress also hurts us - our own organs - such as our heart and brain. If our immune system works hard for quite some time, we increase the risk of organ dysfunction. Increased oxidative stress in our brain may predispose us to loss of smell and taste. Thus, overcome the infection by supporting your immune system. Then clean up the damage caused by your immune system by using antioxidants. Antioxidants which are very effective for your brain and other areas: - PQQ - Glutathione - SOD - Alpha-R-Lipoic Acid - NAC Where to buy antioxidants: https://www.seekinghealth.com/collections/antioxidant-supplements Research: https://www.aarp.org/health/brain-health/info-2017/sense-of-smell-loss-dementia-fd.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309413/pdf/OMCL2017-3496043.pdf https://elifesciences.org/articles/32018 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625946/pdf/nihms-1013286.pdf https://onlinelibrary.wiley.com/doi/abs/10.1097/00005537-200211000-00031 https://dta0yqvfnusiq.cloudfront.net/nascent-health/2017/09/PQQ-Short-Version-59bd304fa70bf.pdf